scholarly journals Epicardial adipose tissue volume predicts long term major adverse cardiovascular events in patients with Type 2 diabetes

2021 ◽  
Vol 49 (2) ◽  
pp. 127-134
Author(s):  
Begum Uygur ◽  
◽  
Omer Celik ◽  
Ali Riza Demir ◽  
Muammer Karakayali ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Cardiovascular Events ◽  
Epicardial Adipose Tissue ◽  
Major Adverse Cardiovascular Events ◽  
Tissue Volume ◽  
Adipose Tissue Volume

Effect of Type 2 Diabetes Mellitus on Epicardial Adipose Tissue Volume and Coronary Vasomotor Function

2014 ◽  
Vol 113 (1) ◽  
pp. 90-97 ◽  
Author(s):  
Weena J.Y. Chen ◽  
Ibrahim Danad ◽  
Pieter G. Raijmakers ◽  
Rick Halbmeijer ◽  
Hendrik J. Harms ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adipose Tissue ◽  
Epicardial Adipose Tissue ◽  
Tissue Volume ◽  
Vasomotor Function ◽  
Adipose Tissue Volume ◽  
Coronary Vasomotor Function

scholarly journals Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes

2020 ◽  
Vol 22 (7) ◽  
pp. 1094-1101 ◽  
Author(s):  
Lars Johansson ◽  
Paul D. Hockings ◽  
Eva Johnsson ◽  
Nalina Dronamraju ◽  
Jill Maaske ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Liver Fat ◽  
Tissue Volume ◽  
Adipose Tissue Volume

scholarly journals The Natural history of Epicardial Adipose Tissue Volume and Attenuation: A long-term prospective cohort follow-up study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Nitesh Nerlekar ◽  
Udit Thakur ◽  
Andrew Lin ◽  
Ji Quan Samuel Koh ◽  
Elizabeth Potter ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Natural History ◽  
Prospective Cohort ◽  
Epicardial Adipose Tissue ◽  
Tissue Volume ◽  
Follow Up Study ◽  
History Of ◽  
Adipose Tissue Volume

Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1175-P
Author(s):  
JOHN P. WILDING ◽  
PAUL HOCKINGS ◽  
EVA K. JOHNSSON ◽  
JILL MAASKE ◽  
RICARDO GARCIA-SANCHEZ ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Liver Fat ◽  
Tissue Volume ◽  
Adipose Tissue Volume

Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes

2020 ◽  
Author(s):  
Jonas Ghouse ◽  
Paul Blanche ◽  
Morten W Skov ◽  
Bent Lind ◽  
Allan Vaag ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Events ◽  
Major Adverse Cardiovascular Events ◽  
Short Term ◽  
Oral Antidiabetic ◽  
Steep Decline ◽  
Pre Treatment ◽  
First Time

Abstract Aims To determine the risk of major adverse cardiovascular events (MACE) and death, associated with an early large and rapid decline in glycated haemoglobin (HbA1C) following first time initiation of an oral antidiabetic drug (OAD). Methods and results We included 10 518 primary care patients with type 2 diabetes, who initiated an OAD for the first time. For each individual, we measured a decline in HbA1C, as the difference between the pre-treatment HbA1C (within 3 months before OAD initiation) and the post-treatment HbA1C (within 1.5–4.5 months after OAD initiation), divided by the time between the two measurements. The decline was reported in mmol/mol change per 3 months in HbA1C and categorized by the median decline into levels of steep [≥9 mmol/mol (≥0.8%)] and flat decline [<9 mmol/mol per 3 months (<0.8%)]. Pre-treatment HbA1C was categorized by the median, into levels of low (48–62 mmol/mol) and high (>62 mmol/mol). Multiple Cox regression was used to study the effect of decline (steep vs. flat) on the outcome hazard rates separately for patients with low and high pre-treatment HbA1C. Analyses were adjusted for age, sex, traditional cardiovascular risk factors, severe comorbidities, and concomitant medication treatment. During a median follow-up time of 7.7 years, 1625 developed MACE and 2323 died. We found that a steep decline vs. a flat decline was significantly associated with a decreased hazard for MACE, both in individuals with high [hazard ratio (HR) 0.81; 95% confidence interval (CI) 0.69–0.94; P = 0.005] and low pre-treatment HbA1C (HR 0.79; 95% CI 0.66–0.96; P = 0.015). The hazard of MACE was more pronounced on the short-term vs. long-term in individuals with high pre-treatment HbA1C. We found no significant association between combinations of pre-treatment HbA1C and decline categories and hazard of all-cause mortality. However, a combination of a low pre-treatment HbA1C and steep decline was associated with increased 1-year mortality (HR 1.52; 95% CI 1.00–2.29; P = 0.048) and hypoglycaemia (HR 1.82; 95% CI 1.11–2.98; P = 0.017). Conclusion A combination of a high pre-treatment HbA1C and a steep decline in HbA1C was associated with a decreased short-term risk of MACE. A low pre-treatment HbA1C and a steep decline was associated with a long-term reduced risk of MACE, but a short-term increased risk of death and hypoglycaemia.

Sign in / Sign up

Export Citation Format

Share Document